ASCP Corner: Clinical Psychopharmacology of Pediatric Mood Stabilizer and Antipsychotic Treatment, Part 1: Challenges and Developments
J Clin Psychiatry 2007;68(8):1301-1302
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
The field of clinical psychopharmacology has a long and productive history. Only recently, however, has the field begun to include children and adolescents on a larger scale. Reasons for this delay include concerns about safety and tolerability in this vulnerable population, diagnostic uncertainties, and the reluctance of the industry to embark on pediatric registration and labeling studies for diagnoses that traditionally have not been seen as predominant disorders of childhood and adolescence.